Form 8-K - Current report:
SEC Accession No. 0001104659-25-019127
Filing Date
2025-02-28
Accepted
2025-02-28 16:05:27
Documents
13
Period of Report
2025-02-27
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm257957d1_8k.htm   iXBRL 8-K 23889
  Complete submission text file 0001104659-25-019127.txt   197769

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA lvtx-20250227.xsd EX-101.SCH 3039
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE lvtx-20250227_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lvtx-20250227_pre.xml EX-101.PRE 22375
16 EXTRACTED XBRL INSTANCE DOCUMENT tm257957d1_8k_htm.xml XML 3668
Mailing Address YALELAAN 62 UTRECHT P7 3584 CM
Business Address YALELAAN 62 UTRECHT P7 3584 CM 31 6 3000 3035
LAVA Therapeutics NV (Filer) CIK: 0001840748 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40241 | Film No.: 25690004
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)